<DOC>
	<DOCNO>NCT02432911</DOCNO>
	<brief_summary>This study focus comparison CAG regimen low dose cytarabine therapy elderly AML patient unfit unwilling receive intensive chemotherapy .</brief_summary>
	<brief_title>Treatment Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 75 Years Old</brief_title>
	<detailed_description>Low dose cytarabine remain choice standard elderly AML patient unfit unwilling receive intensive treatment . CAG regimen , combination aclacinomycin，low dose cytarabine±G-CSF use often elderly AML patient China . It prove effective safety pilot studies，while prospective，randomized study yet .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Aclacinomycins</mesh_term>
	<mesh_term>Aclarubicin</mesh_term>
	<criteria>Acute myeloid leukemia except APL ECOG PS：03 Unfit unwilling receive intensive therapy The one already receive induction therapy matter outcome . Active cancer patient need receive treatment ; Serious uncontrolled infectious disease ( eg.tuberculosis invasive pulmonary aspergillosis）； Active heart disease</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>